Pharma Focus Asia

AbbVie's drug for all types of hepatitis C wins EU approval

Monday, July 31, 2017

AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C.

The company said the approval of Maviret was supported by eight studies evaluating more than 2,300 patients in 27 countries.

The drug, a combination of glecaprevir and pibrentasvir, showed 97.5 percent cure rate in the eight weeks of treatment of patients, who have never undergone treatment.

The drug is also under priority review by the U.S. Food and Drug Administration and the company expects regulatory decisions in the coming weeks.

The FDA last year approved a combination drug, a 12-week regimen by Gilead Sciences Inc for the treatment for all six major forms of hepatitis C for patients who've already tried one drug.

AbbVie also competes with companies such as Merck & Co in the hepatitis C market.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024